On September 1, 2021 Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported that it is scheduled to participate in the following upcoming events (Press release, Arrowhead Pharmaceuticals, SEP 1, 2021, View Source [SID1234587183]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi’s 16th Annual BioPharma Virtual Conference – September 8-10, 2021
September 9, 2021 – Arrowhead management will host a day of virtual investor meetings

HC Wainwright 23rd Annual Global Investment Conference – September 13-15, 2021
September 13, 2021 – Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation

Baird’s 2021 Global Healthcare Conference – September 14-15, 2021
September 14, 2021, 4:55 p.m. ET – Vince Anzalone, CFA, Arrowhead’s vice president of investor relations, will participate in a fireside chat presentation

2021 Cantor Virtual Global Healthcare Conference – September 27-30, 2021
September 29, 2021, 9:20 a.m. ET – Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation

A copy of the presentation materials and/or live webcast links may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

On September 1, 2021 Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, reported that it will report financial results for the first quarter of fiscal year 2022 on September 8, 2021 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time) (Press release, Avid Bioservices, SEP 1, 2021, View Source [SID1234587092]). Members of Avid’s senior management will discuss financial results for the first quarter and review recent corporate developments.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To listen to the live webcast, or access the archived webcast, please visit: View Source

To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Avid Bioservices call.

On September 1, 2021 Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, reported plans to host a live conference call and webcast on Friday, September 10, 2021 at 8:00 a.m. ET to discuss the progress of its clinical development strategy for upifitamab rilsodotin (UpRi) and report updated interim data from the ovarian cancer expansion cohort of the UpRi Phase 1 study (Press release, Mersana Therapeutics, SEP 1, 2021, View Source [SID1234587110]). Enrollment in the expansion cohort is complete with 97 patients evaluable for safety and tolerability, of which 75 are RECIST-evaluable at this interim analysis.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Members of the Mersana executive team will be joined by lead investigator, Debra L. Richardson, MD Associate Professor and Section Chief of Gynecologic Oncology at the Stephenson Cancer Center at the University of Oklahoma Health Sciences Center and the Sarah Cannon Research Institute.

Conference Call Details
To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 1441618. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com.

On September 1, 2021 Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, reported that Bill Newell, Chief Executive Officer, will participate in the 2021 Wells Fargo Securities Healthcare Conference during a virtual fireside chat on Thursday, September 9, at 3:20 p.m. ET / 12:20 p.m. PT (Press release, Sutro Biopharma, SEP 1, 2021, View Source [SID1234587129]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be accessible through the News and Events page of the Investor Relations section on the company’s website at www.sutrobio.com. Archived replays of the webcasts will be available on the company’s website for approximately 30 days following each live presentation.

On September 1, 2021 Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (Nasdaq: ZIOP), reported that Kevin S. Boyle, Sr., Chief Executive Officer of Ziopharm, is scheduled to participate in five upcoming virtual investor conferences (Press release, Ziopharm, SEP 1, 2021, View Source [SID1234587093]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2021 Wells Fargo Virtual Healthcare Conference
Date: September 9, 2021
Presentation Time: 10:00 am EDT

Morgan Stanley 19th Annual Global Healthcare Conference
Date: September 10, 2021
No presentation – management available for one-on-one meetings

H.C. Wainwright 23rd Annual Global Investment Conference
Date: September 13, 2021
Time: 7:00 am EDT (access to on demand webcast begins)

Lake Street 5th Annual Best Ideas Growth Conference
Date: September 15, 2021
No presentation – management available for one-on-one meetings

2021 Cantor Virtual Global Healthcare Conference
Date: September 28, 2021
Presentation Time: 3:20 pm EDT

"As one of my initial priorities as CEO, I seek to meet with our existing shareholders and hearing their perspectives," said Mr. Boyle. "I also welcome the opportunity to introduce Ziopharm’s cutting-edge TCR science to potential new investors."

To access the webcast presentations, or the subsequent archived recordings, please see the links above or visit the "Investors" section of the Ziopharm website at www.ziopharm.com.